Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
749 13 |
Ultima descărcare din IBN: 2023-06-16 15:42 |
Căutarea după subiecte similare conform CZU |
616.36–002 (2) |
Patologia sistemului digestiv. Tulburări ale tubului alimentar (1732) |
SM ISO690:2012 АГАЕВА, Гюльнара, ГИДАЯТОВ, Алигусейн. Гепатит Dельта: современное состояние проблемы(литературный обзор). In: Sănătate Publică, Economie şi Management în Medicină , 2017, nr. 4(74), pp. 85-92. ISSN 1729-8687. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Sănătate Publică, Economie şi Management în Medicină | ||||||
Numărul 4(74) / 2017 / ISSN 1729-8687 /ISSNe 2587-3873 | ||||||
|
||||||
CZU: 616.36–002 | ||||||
Pag. 85-92 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Hepatitis Delta is the most severe form of viral hepatitis in humans. The hepatitis Delta virus (HDV) is a defective RNA virus, which requires the hepatitis B virus (HBV) surface antigen (HBsAg) for complete replication and transmission. Several studies have shown that chronic HDV infection leads to more severe liver diseases than chronic HBV mono-infection, with an accelerated course of fibrosis progression, possibility of a slightly increased risk of hepatocellular carcinoma development and early decompensation in the setting of established cirrhosis. Only interferon-alfa treatment has been shown to exert some antiviral activity against HDV and has been linked to improve the clinical long-term outcome. Data on the use of PEGylated interferon (PEG-IFN) confirm earlier findings, leading to prolonged virological off-treatment responses in about one quarter of patients, but long-term HDV RNA relapses may occur. HBsAg clearance should be the preferred endpoint of interferon-based therapies of HDV. Alternative treatment options including HBV entry inhibitors and prenylation inhibitors are currently in early clinical development. |
||||||
Cuvinte-cheie hepatitis delta virus, HDV infection, HDV treatment |
||||||
|